C
Chul Ho Kim
Researcher at Korea Research Institute of Bioscience and Biotechnology
Publications - 132
Citations - 2503
Chul Ho Kim is an academic researcher from Korea Research Institute of Bioscience and Biotechnology. The author has contributed to research in topics: Fermentation & Levansucrase. The author has an hindex of 26, co-authored 130 publications receiving 2187 citations.
Papers
More filters
Journal ArticleDOI
Bacterial Expression and Purification of Human Papillomavirus Type 18 L1
TL;DR: This expression and purification system offers a simple method of expressing and purifying HPV L1 protein, and could potentially be an effective route for the development and manufacturing of highly purified HPV-18 L1-based cervical cancer vaccines.
Journal ArticleDOI
Effect of galactose feeding on the improved production of hirudin in fed-batch cultures of recombinant Saccharomyces cerevisiae
TL;DR: A step-wise feeding of Galactose was found as more suitable feeding strategy of galactose which resulted in the final hirudin volumetric productivity of 6,840 μg/l · h, than intermittent, continuous and ethanol controlled feeding ofGalactose.
Journal ArticleDOI
Analytical Techniques for Vancomycin - A Review
TL;DR: The present review deals with the qualitative, quantitative, microbiological and immunological assays and the comparison of the quantitative methods of vancomycin.
Journal ArticleDOI
Molecular cloning of levan fructotransferase gene from Arthrobacter ureafaciens K2032 and its expression in Escherichia coli for the production of difructose dianhydride IV
Chul Ho Kim,E K Jang,Soonchoen Kim,K H Jang,Kang Sang-Hyeon,Ki-Bang Song,Oh Suk Kwon,Sang Ki Rhee +7 more
TL;DR: Aims: To clone and overexpress a novel levan fructotransferase gene lftA from Arthrobacter ureafaciens K2032.
Journal ArticleDOI
Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer
TL;DR: Developing a VLP production and delivery system using B. subtilis will be helpful, in that the vaccine may be convenient production as an antigen delivery system and VLPs thus produced will be safer for human use than those purified from Gram-negative strains such as Escherichia coli.